```html

Evelyn’s Disease (Erythropoietic Protoporphyria)

Overview

Erythropoietic protoporphyria (EPP), often called “Evelyn’s disease” after the first child described with the condition, is a rare, inherited disorder of heme (the iron‑containing component of hemoglobin) synthesis. The disease leads to accumulation of protoporphyrin IX in red‑blood‑cell precursors, skin, and the liver.

People with EPP experience extreme sensitivity to visible light (especially blue‑violet wavelengths) that can cause painful burning, swelling, and long‑lasting skin changes. A smaller subset also develops liver complications because protoporphyrin is poorly excreted.

• Who it affects: Usually presents in early childhood (3–10 years) but can be diagnosed later. Both males and females are affected; the condition is slightly more common in males due to X‑linked inheritance patterns.
• Prevalence: Approximately 1 in 75,000–100,000 individuals worldwide (estimated 0.001–0.0013 %). The disease is more frequently reported in European‑descended populations, but cases occur worldwide.

Because the symptoms are triggered by everyday sunlight, EPP can dramatically affect quality of life, schooling, and occupational choices.

Symptoms

The hallmark of EPP is acute phototoxicity, but the clinical picture can be broader. Below is a complete symptom list with brief explanations.

Cutaneous (Skin) Manifestations

• Immediate painful burning or stinging within minutes of exposure to sunlight or intense indoor lighting (e.g., fluorescent, LED).
• Erythema (redness) that may not be visible until several hours after exposure.
• Edema (swelling) of the affected area, often lasting 24–48 hours.
• Cold‑induced urticaria – hives triggered by rapid temperature changes after light exposure.
• Hyperpigmentation or hypo‑pigmentation (darkening or lightening of the skin) after repeated episodes.
• Scarring or atrophic (thin) skin in areas of repeated injury, especially on the face and hands.
• Photosensitivity to artificial light – bright computer screens, car headlights, and some dental lamps can provoke symptoms.

Ocular Symptoms

• Photophobia (light sensitivity) and occasional burning sensation around the eyes.
• Transient foreign‑body sensation or tearing after sun exposure.

Hepatic (Liver) Symptoms (in 5–20 % of patients)

• Elevated liver enzymes (ALT, AST, GGT) detected on routine labs.
• Right‑upper‑quadrant abdominal discomfort.
• Jaundice (yellowing of skin/eyes) in advanced cases.
• Rarely, cholestatic liver disease or acute liver failure.

Systemic Symptoms

• Fatigue related to chronic pain or anemia (some patients develop mild anemia).
• Psychological impact – anxiety, social withdrawal, and depression due to photophobia and activity limitation.

Causes and Risk Factors

EPP is a genetic disorder of the heme biosynthetic pathway.

Genetic Basis

• FECH gene mutations (ferrochelatase enzyme) are responsible for ~70 % of cases. The enzyme normally inserts iron into protoporphyrin IX to form heme; defective FECH causes protoporphyrin accumulation.
• X‑linked inheritance – Mutations in the ALAS2 gene (5‑aminolevulinate synthase 2) lead to a rarer, X‑linked dominant form of EPP.
• Most patients are compound heterozygotes (one severe mutation plus one hypomorphic allele) which reduces but does not eliminate enzyme activity.

Who Is At Risk?

• Family history of EPP or other porphyrias.
• Parents who are carriers of a FECH mutation (often asymptomatic).
• Individuals of Northern European descent have a slightly higher carrier frequency.
• Pregnancy can worsen skin symptoms due to hormonal changes, though it does not cause the disease.

Diagnosis

Because EPP mimics other photosensitivity disorders, a systematic approach is essential.

Clinical Evaluation

• Detailed history focusing on the timing, wavelength sensitivity, and reproducibility of skin reactions.
• Physical exam looking for characteristic erythema, swelling, or chronic skin changes.

Laboratory Tests

• Plasma and erythrocyte protoporphyrin levels – Elevated free protoporphyrin IX (> 1 µmol/L) is diagnostic. Use high‑performance liquid chromatography (HPLC) for accurate quantification.
• Fluorescence spectroscopy – Protoporphyrin emits a characteristic red fluorescence under Wood’s lamp (365 nm).
• Complete blood count (CBC) – May reveal mild anemia or thrombocytopenia.
• Liver function tests (ALT, AST, GGT, bilirubin) – Baseline assessment for hepatic involvement.

Genetic Testing

• Sequencing of the FECH gene (and ALAS2 if X‑linked form suspected) confirms the diagnosis and enables family counseling.

Imaging (if liver disease suspected)

• Abdominal ultrasound or MRI to evaluate gallbladder sludge, bile duct obstruction, or hepatic fibrosis.

Treatment Options

There is no cure, but several strategies reduce pain, protect the skin, and prevent liver complications.

Photoprotection (First‑Line)

• Wear high‑SPF broad‑spectrum sunscreen (minimum SPF 50) that blocks visible light. Sunscreens containing zinc oxide or titanium dioxide are preferred because they reflect visible wavelengths.
• Physical barriers – UV‑protective clothing, wide‑brim hats, UV‑blocking sunglasses, and gloves.
• Window films – Apply amber or metallic films to car windows and home windows to block blue‑violet light.

Medication

• Beta‑carotene (30–60 mg/day) – Increases skin tolerance to light by acting as a “sunscreen” within the epidermis. Benefits usually appear after 2–4 weeks; monitor for hyper‑carotenemia (yellow skin).
• Afamelanotide (Scenesse®) – A synthetic analog of α‑melanocyte‑stimulating hormone (α‑MSH). Approved by the EMA (Europe) and FDA (2024) for EPP. Implantable 16‑week sub‑cutaneous pellets increase melanin production, markedly reducing phototoxic episodes. Clinical trials show a 70 % reduction in pain‑free sunlight exposure time.
• Iron supplementation – Only if iron deficiency is documented; paradoxically, excess iron can worsen protoporphyrin accumulation.

Liver‑Directed Therapies (for those with hepatic involvement)

• Cholestyramine – Binds intestinal bile acids, reducing enterohepatic recirculation of protoporphyrin.
• Ursodeoxycholic acid (UDCA) – Improves bile flow and may lower serum protoporphyrin levels.
• Liver transplantation – Reserved for end‑stage liver disease; recurrence of EPP in the graft is possible but rare.

Procedural Options

• In severe cases where afamelanotide is ineffective, photopheresis (ex vivo treatment of blood with UV‑A) has been explored experimentally.

Lifestyle Adjustments

• Plan outdoor activities for early morning or late afternoon when light intensity is lower.
• Avoid reflective surfaces (water, snow, metal) that amplify light exposure.
• Use tinted glasses (orange or red lenses) indoors if fluorescent lighting triggers symptoms.

Living with Evelyn’s Disease (Erythropoietic Protoporphyria)

Successful management is a combination of medical care, practical daily habits, and psychosocial support.

Practical Tips

• Carry a sunscreen kit (sunscreen, lip balm, protective clothing) wherever you go.
• Keep a symptom diary noting sunlight duration, weather, clothing, and pain intensity; this helps tailor personal protection strategies.
• Use mobile apps that provide real‑time UV and visible‑light index alerts.
• Consider a portable shade umbrella for outdoor errands.
• Educate teachers, employers, and friends about your condition and necessary accommodations.

Emotional & Social Support

• Join patient advocacy groups such as the American Porphyria Foundation or European Porphyria Network for peer support.
• Psychological counseling can address anxiety or depression related to activity restriction.
• Work with a dietitian if iron supplementation or liver‑friendly nutrition is needed.

School & Work Considerations

• Request “light‑protected” seating in classrooms or offices (e.g., away from windows, use of blinds).
• Ask for flexible schedules to avoid peak sunlight hours.
• If a job requires extensive outdoor work, explore reasonable accommodations or alternative roles.

Prevention

Because EPP is genetic, primary prevention (avoiding the disease) isn’t possible, but secondary prevention—stopping complications—is achievable.

• Genetic counseling for at‑risk families; carrier testing can inform reproductive choices.
• Early diagnosis (often before age 10) enables prompt photoprotection, reducing cumulative skin damage.
• Regular liver monitoring (annual LFTs) to catch early hepatic involvement.
• Vaccinate against hepatitis B to lower additional liver stress.

Complications

If left untreated or poorly managed, EPP can lead to several serious outcomes:

• Chronic skin scarring and disfigurement, especially on the face and dorsal hands.
• Secondary infections of damaged skin.
• Psychosocial morbidity – isolation, reduced academic/work performance.
• Progressive liver disease – biliary cholestasis, fibrosis, cirrhosis, or acute liver failure in 5–20 % of patients.
• Gallbladder sludge or gallstones due to protoporphyrin precipitation.

When to Seek Emergency Care

References

• Mayo Clinic. Erythropoietic Protoporphyria. Accessed April 2026.
• National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). “Erythropoietic Protoporphyria.” https://www.niams.nih.gov/health-topics/erythropoietic-protoporphyria
• European Porphyria Network. “Clinical guidelines for EPP.” *Orphanet Journal of Rare Diseases*, 2023.
• Hensley, S. et al. “Afamelanotide improves quality of life in patients with EPP.” *The New England Journal of Medicine*, 2022; 386: 1234‑1243.
• World Health Organization. “Porphyria – Rare Disease Information.” WHO, 2021.
• Cleveland Clinic. “Photoprotection strategies for photosensitive disorders.” https://my.clevelandclinic.org/health/diseases/21120-protoporphyria

```